A practical guide about biosimilar data for health care providers treating inflammatory diseases
Joseph Markenson,1,2 Daniel F Alvarez,3 Ira Jacobs,4 Carol Kirchhoff5 1Department of Rheumatology, 2Department of Medicine, Hospital for Special Surgery, New York, NY, 3Pfizer Inc, Collegeville, PA, 4Pfizer Inc, New York, NY, 5Pfizer Inc, Chesterfield, MO, USA Abstract: To make informed dec...
Guardado en:
Autores principales: | Markenson J, Alvarez DF, Jacobs I, Kirchhoff C |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f9f26565da4f46dba6052ea2c7079196 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Biosimilars and the extrapolation of indications for inflammatory conditions
por: Tesser JRP, et al.
Publicado: (2017) -
Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab
por: Yazici Y, et al.
Publicado: (2018) -
Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
por: Al Sulais E, et al.
Publicado: (2020) -
Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
por: Mysler E, et al.
Publicado: (2021) -
A descriptive analysis of real-world treatment patterns of innovator (Remicade®) and biosimilar infliximab in an infliximab-naïve Turkish population
por: Yazici Y, et al.
Publicado: (2018)